Pharmacological inhibition of ERK1/2 activity highlights an indispensable role of ERK1/2 signaling in controlling EMT, MMP9 expression, and the metastatic abilities of cancer cells upon p53 loss. The gene discussed is MAPK3; the disease is cancer.